Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
出版年份 2015 全文链接
标题
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
作者
关键词
-
出版物
Diabetes & Vascular Disease Research
Volume 12, Issue 3, Pages 154-163
出版商
SAGE Publications
发表日期
2015-02-13
DOI
10.1177/1479164114562411
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants
- (2014) Shiying Wu et al. Cardiovascular Therapeutics
- Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition
- (2014) Jessica K. Devin et al. HYPERTENSION
- Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials
- (2014) M. Monami et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
- (2013) Jennifer B. Green et al. AMERICAN HEART JOURNAL
- Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression
- (2013) M. Katout et al. AMERICAN JOURNAL OF HYPERTENSION
- Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
- (2013) Wendy L. Bennett et al. ANNALS OF INTERNAL MEDICINE
- Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors
- (2013) M. Barbieri et al. ATHEROSCLEROSIS
- Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Improves Endothelial Dysfunction in Association With Its Anti-Inflammatory Effects in Patients With Coronary Artery Disease and Uncontrolled Diabetes
- (2013) Junichi Matsubara et al. CIRCULATION JOURNAL
- Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial
- (2013) Julio Rosenstock et al. Diabetes & Vascular Disease Research
- A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks
- (2013) M. A. Nauck DIABETES CARE
- Cardiovascular Outcome Studies With Novel Antidiabetes Agents: Scientific and Operational Considerations
- (2013) B. Hirshberg et al. DIABETES CARE
- A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 therapies safe?
- (2013) P. C. Butler et al. DIABETES CARE
- Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
- (2013) W. B. White et al. DIABETES OBESITY & METABOLISM
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic Patients
- (2013) Makoto Ayaori et al. Journal of the American Heart Association
- DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
- (2012) Matteo Monami et al. ADVANCES IN THERAPY
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
- (2012) Odd Johansen et al. Cardiovascular Diabetology
- Individualizing Targets and Tactics for High-Risk Patients With Type 2 Diabetes: Practical lessons from ACCORD and other cardiovascular trials
- (2012) M. C. Riddle et al. DIABETES CARE
- Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
- (2012) M. Monami et al. DIABETES OBESITY & METABOLISM
- Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study
- (2012) B. Eliasson et al. DIABETOLOGIA
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- Dipeptidyl Peptidase 4 Inhibition Increases Myocardial Glucose Uptake in Nonischemic Cardiomyopathy
- (2012) Ronald M. Witteles et al. JOURNAL OF CARDIAC FAILURE
- Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Enhanced Nitric Oxide Release and Reduced Blood Pressure and sICAM-1 Levels in Hypertensive Rats
- (2012) R. Preston Mason et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus
- (2012) Michael Cobble Diabetology & Metabolic Syndrome
- Gut-liver interaction in triglyceride-rich lipoprotein metabolism
- (2011) Changting Xiao et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
- (2011) Meimei Yin et al. Cardiovascular Diabetology
- Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
- (2011) Zubair Shah et al. CIRCULATION
- Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
- (2011) D. Lamers et al. DIABETES
- Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
- (2011) P. C. M. van Poppel et al. DIABETES CARE
- Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs
- (2011) B. Hirshberg et al. DIABETES CARE
- DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors
- (2011) D. Dicker DIABETES CARE
- The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients
- (2011) G. P. Fadini et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure
- (2011) Nelson Gomez et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of Enhanced Glycemic Control with Saxagliptin on Endothelial Nitric Oxide Release and CD40 Levels in Obese Rats
- (2011) R. Preston Mason et al. Journal of Atherosclerosis and Thrombosis
- DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice
- (2011) Nga N Ta et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Inflammatory links between obesity and metabolic disease
- (2011) Carey N. Lumeng et al. JOURNAL OF CLINICAL INVESTIGATION
- HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms
- (2011) Mohamad Navab et al. Nature Reviews Cardiology
- Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy
- (2011) Lyubov Chaykovska et al. PLoS One
- Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus
- (2010) Eric A. Schwartz et al. ATHEROSCLEROSIS
- DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease
- (2010) Philip A. Read et al. Circulation-Cardiovascular Imaging
- Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice
- (2010) M. Sauve et al. DIABETES
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1
- (2010) G. P. Fadini et al. DIABETES CARE
- Cardiovascular Disease in Type 2 Diabetes From Population to Man to Mechanisms: The Kelly West Award Lecture 2008
- (2010) M. Laakso DIABETES CARE
- Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
- (2010) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults
- (2010) Elizabeth Selvin et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
- (2010) Robert Frederich et al. POSTGRADUATE MEDICINE
- Synergy between CD26/DPP-IV Inhibition and G-CSF Improves Cardiac Function after Acute Myocardial Infarction
- (2009) Marc-Michael Zaruba et al. Cell Stem Cell
- Endothelial Function Predicts Progression of Carotid Intima-Media Thickness
- (2009) Julian P.J. Halcox et al. CIRCULATION
- Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary Atherosclerosis
- (2009) P. D. Reaven et al. DIABETES
- Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
- (2008) Ralph A. DeFronzo et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
- (2008) Debora Williams-Herman et al. BMC Endocrine Disorders
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started